GBT Financial Facts

Selling, general and administrative expenses: 2.08M
Research and development expenses: 298.26K
See Full Income Statement

Deferred tax liability: 3.03M
Investment - equity in affiliate: 763.97K
See Full Balance Sheet

Global Blood Therapeutics (GBT) Earnings

  |   Expand Research on GBT
Next EPS Date 2/23/23 *Est. EPS Growth Rate N/A
Average EPS % Beat Rate -1.8% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS -6.7% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/3/21 Q221 -$1.12-$1.19 +$0.07$47.6M$43.84M N/A Details
11/9/16 Q316 -$0.58-$0.58 $0.00N/AN/A N/A Details
8/10/16 Q216 -$0.58N/A N/A N/AN/A N/A Details
2/23/22 Q421 -$1.36-$1.13 -$0.23$56.1M$55.44M N/A Details
5/1/17 Q117 -$0.60N/A N/A N/AN/A N/A Details
8/5/20 Q220 N/A-$1.15 N/A N/A$19.03M N/A N/A N/A
5/6/20 Q120 N/A-$1.51 N/A N/A$3.66M N/A N/A N/A
11/3/22 Q322 N/A-$1.12 N/A N/A$75.79M N/A N/A N/A